Staying Informed on Knee Osteoarthritis Therapies: Latest Developments
Is the Market Shifting Toward Single IA-HA Injections? Knee Osteoarthritis (KOA) affects millions worldwide, leading to pain and reduced mobility. While traditional treatments include nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy, the market is shifting towards single intra-articular hyaluronic acid (IA-HA) injections as a promising alternative. These injections provide symptomatic relief and potentially slow down disease progression. Joyclu’s Approval in Japan The recent approval of Joyclu in Japan has stirred excitement in the KOA market. Joyclu, developed by Seikagaku Corporation, is a sodium hyaluronate injection for the treatment of knee osteoarthritis. This approval marks a significant milestone and opens doors for innovative therapies in other regions. The Scenario of Emerging Therapies Numerous emerging therapies are in the pipeline, offering hope to Knee Osteoarthritis patients. Promising candidates like CNTX-4975, Sprifermin, and Lorecivivint are...